Atea Pharmaceuticals (AVIR) Competitors $3.67 +0.04 (+1.10%) Closing price 07/3/2025 03:40 PM EasternExtended Trading$3.65 -0.02 (-0.54%) As of 07/3/2025 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVIR vs. AUPH, BGM, NAGE, AMPH, DYN, ABCL, PAHC, WVE, ELVN, and VERVShould you be buying Atea Pharmaceuticals stock or one of its competitors? The main competitors of Atea Pharmaceuticals include Aurinia Pharmaceuticals (AUPH), BGM Group (BGM), Niagen Bioscience (NAGE), Amphastar Pharmaceuticals (AMPH), Dyne Therapeutics (DYN), AbCellera Biologics (ABCL), Phibro Animal Health (PAHC), WAVE Life Sciences (WVE), Enliven Therapeutics (ELVN), and Verve Therapeutics (VERV). These companies are all part of the "pharmaceutical products" industry. Atea Pharmaceuticals vs. Its Competitors Aurinia Pharmaceuticals BGM Group Niagen Bioscience Amphastar Pharmaceuticals Dyne Therapeutics AbCellera Biologics Phibro Animal Health WAVE Life Sciences Enliven Therapeutics Verve Therapeutics Atea Pharmaceuticals (NASDAQ:AVIR) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk. Do institutionals & insiders hold more shares of AVIR or AUPH? 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 18.1% of Atea Pharmaceuticals shares are owned by company insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts recommend AVIR or AUPH? Atea Pharmaceuticals presently has a consensus target price of $6.00, suggesting a potential upside of 63.49%. Aurinia Pharmaceuticals has a consensus target price of $11.50, suggesting a potential upside of 52.00%. Given Atea Pharmaceuticals' higher possible upside, research analysts clearly believe Atea Pharmaceuticals is more favorable than Aurinia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Aurinia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings and valuation, AVIR or AUPH? Aurinia Pharmaceuticals has higher revenue and earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtea PharmaceuticalsN/AN/A-$168.38M-$1.65-2.22Aurinia Pharmaceuticals$235.13M4.35$5.75M$0.2827.02 Is AVIR or AUPH more profitable? Aurinia Pharmaceuticals has a net margin of 16.11% compared to Atea Pharmaceuticals' net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 14.27% beat Atea Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Atea PharmaceuticalsN/A -31.26% -29.27% Aurinia Pharmaceuticals 16.11%14.27%9.93% Which has more risk & volatility, AVIR or AUPH? Atea Pharmaceuticals has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Does the media favor AVIR or AUPH? In the previous week, Aurinia Pharmaceuticals had 8 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 9 mentions for Aurinia Pharmaceuticals and 1 mentions for Atea Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 0.36 beat Atea Pharmaceuticals' score of 0.00 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aurinia Pharmaceuticals 1 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAurinia Pharmaceuticals beats Atea Pharmaceuticals on 12 of the 15 factors compared between the two stocks. Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVIR vs. The Competition Export to ExcelMetricAtea PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$320.07M$2.91B$5.55B$9.04BDividend YieldN/A2.44%5.22%4.00%P/E Ratio-2.2221.5627.6420.24Price / SalesN/A275.02417.15117.30Price / CashN/A42.7336.8958.10Price / Book0.717.518.035.67Net Income-$168.38M-$55.14M$3.18B$249.21M7 Day Performance6.38%4.61%2.93%3.28%1 Month Performance15.41%0.90%1.72%3.95%1 Year Performance12.92%5.40%34.39%20.98% Atea Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVIRAtea Pharmaceuticals2.3686 of 5 stars$3.67+1.1%$6.00+63.5%+12.9%$320.07MN/A-2.2270AUPHAurinia Pharmaceuticals3.082 of 5 stars$8.47-2.0%$11.50+35.8%+34.9%$1.17B$235.13M30.25300Positive NewsBGMBGM GroupN/A$10.59-11.5%N/AN/A$1.16B$25.10M0.00298News CoverageAnalyst DowngradeGap UpNAGENiagen Bioscience1.3214 of 5 stars$14.41+1.3%$19.50+35.3%+406.4%$1.12B$99.60M84.76120AMPHAmphastar Pharmaceuticals4.3658 of 5 stars$22.96-0.5%$32.33+40.8%-38.6%$1.09B$731.97M8.322,028News CoverageDYNDyne Therapeutics3.5007 of 5 stars$9.52-0.5%$41.13+332.0%-73.7%$1.09BN/A-2.65100ABCLAbCellera Biologics2.4686 of 5 stars$3.43-5.0%$8.33+143.0%+41.4%$1.08B$28.83M-6.12500High Trading VolumePAHCPhibro Animal Health3.6433 of 5 stars$25.54-0.5%$21.80-14.6%+66.1%$1.04B$1.02B32.741,940WVEWAVE Life Sciences4.3632 of 5 stars$6.50-2.5%$20.50+215.4%+27.4%$1.04B$108.30M-7.74240ELVNEnliven Therapeutics2.5077 of 5 stars$20.06-3.0%$39.60+97.4%-7.8%$1.01BN/A-10.4550Analyst ForecastAnalyst RevisionVERVVerve Therapeutics3.4317 of 5 stars$11.23-0.6%$14.57+29.8%+113.8%$1.01B$32.33M-5.32110 Related Companies and Tools Related Companies Aurinia Pharmaceuticals Alternatives BGM Group Alternatives Niagen Bioscience Alternatives Amphastar Pharmaceuticals Alternatives Dyne Therapeutics Alternatives AbCellera Biologics Alternatives Phibro Animal Health Alternatives WAVE Life Sciences Alternatives Enliven Therapeutics Alternatives Verve Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVIR) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.The robotics revolution is here. And it's set to impact everything from how we manufacture goods to how we ...Weiss Ratings | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
